Innovent Biologics Inc (6IB) — Capital Reinvestment Ratio
Latest as of December 2020:
0.97x
Innovent Biologics Inc (6IB) has a Capital Reinvestment Ratio of 0.97x as of December 2020, meaning it reinvests 1% of its operating cash flow (€217.96 Million) in capital expenditures (€211.14 Million). See cash generation quality of Innovent Biologics Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.97x
Capex / Operating Cash Flow
Operating Cash Flow
€217.96 Million
EUR
Capital Expenditures
€211.14 Million
EUR
Data as of
Dec 2020
Most recent filing
Innovent Biologics Inc Capital Reinvestment Ratio (2023–2025)
This chart tracks Innovent Biologics Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Innovent Biologics Inc (2023–2025)
Year-by-year Capital Reinvestment Ratio for Innovent Biologics Inc from 2023 to 2025. For live market cap and broader valuation context, see market value of Innovent Biologics Inc.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €10.00 Billion | €683.27 Million | ▼ -94.8% |
| 2024 | 1.33x | €1.29 Billion | €1.71 Billion | ▼ -85.8% |
| 2023 | 9.36x | €147.81 Million | €1.38 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow